One step closer to the end of postoperative radioactive iodine thyroid remnant ablation

Frederik A. Verburg; Bart de Keizer

doi:10.1016/S2213-8587(24)00306-1

One step closer to the end of postoperative radioactive iodine thyroid remnant ablation

Frederik A. Verburg^*
, Bart de Keizer

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

According to various guidelines and consensus papers, postoperative radioiodine therapy can be prescribed to patients with differentiated thyroid cancer to achieve one of three goals: ablation of essentially healthy thyroid remnant tissue, adjuvant treatment, or treatment of known disease. Each of these goals is associated with different radioactive iodine (131I) activities.1,2 Of these, remnant ablation has been the subject of intense scientific discussion, but the debate has been hampered by the lack of high-quality, prospective, randomised trials. However, with the ESTIMABL2 trial3 and the IoN trial,4 this lack of high-quality evidence is now in the process of being eliminated.

Original language	English
Pages (from-to)	5-6
Number of pages	2
Journal	The Lancet Diabetes and Endocrinology
Volume	13
Issue number	1
Early online date	22 Nov 2024
DOIs	https://doi.org/10.1016/S2213-8587(24)00306-1
Publication status	Published - Jan 2025

Access to Document

10.1016/S2213-8587(24)00306-1

PIIS2213858724003061Final published version, 176 KBLicence: Taverne

Cite this

@article{a0c17b4237564232ae0b0aef81b9712e,

title = "One step closer to the end of postoperative radioactive iodine thyroid remnant ablation",

abstract = "According to various guidelines and consensus papers, postoperative radioiodine therapy can be prescribed to patients with differentiated thyroid cancer to achieve one of three goals: ablation of essentially healthy thyroid remnant tissue, adjuvant treatment, or treatment of known disease. Each of these goals is associated with different radioactive iodine (131I) activities.1,2 Of these, remnant ablation has been the subject of intense scientific discussion, but the debate has been hampered by the lack of high-quality, prospective, randomised trials. However, with the ESTIMABL2 trial3 and the IoN trial,4 this lack of high-quality evidence is now in the process of being eliminated.",

author = "Verburg, \{Frederik A.\} and \{de Keizer\}, Bart",

year = "2025",

month = jan,

doi = "10.1016/S2213-8587(24)00306-1",

language = "English",

volume = "13",

pages = "5--6",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier Limited",

number = "1",

}

TY - JOUR

T1 - One step closer to the end of postoperative radioactive iodine thyroid remnant ablation

AU - Verburg, Frederik A.

AU - de Keizer, Bart

PY - 2025/1

Y1 - 2025/1

N2 - According to various guidelines and consensus papers, postoperative radioiodine therapy can be prescribed to patients with differentiated thyroid cancer to achieve one of three goals: ablation of essentially healthy thyroid remnant tissue, adjuvant treatment, or treatment of known disease. Each of these goals is associated with different radioactive iodine (131I) activities.1,2 Of these, remnant ablation has been the subject of intense scientific discussion, but the debate has been hampered by the lack of high-quality, prospective, randomised trials. However, with the ESTIMABL2 trial3 and the IoN trial,4 this lack of high-quality evidence is now in the process of being eliminated.

AB - According to various guidelines and consensus papers, postoperative radioiodine therapy can be prescribed to patients with differentiated thyroid cancer to achieve one of three goals: ablation of essentially healthy thyroid remnant tissue, adjuvant treatment, or treatment of known disease. Each of these goals is associated with different radioactive iodine (131I) activities.1,2 Of these, remnant ablation has been the subject of intense scientific discussion, but the debate has been hampered by the lack of high-quality, prospective, randomised trials. However, with the ESTIMABL2 trial3 and the IoN trial,4 this lack of high-quality evidence is now in the process of being eliminated.

UR - https://www.scopus.com/pages/publications/85211329705

U2 - 10.1016/S2213-8587(24)00306-1

DO - 10.1016/S2213-8587(24)00306-1

M3 - Comment/Letter to the editor

C2 - 39586308

AN - SCOPUS:85211329705

SN - 2213-8587

VL - 13

SP - 5

EP - 6

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 1

ER -

One step closer to the end of postoperative radioactive iodine thyroid remnant ablation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this